NA
MRSN

Nordwand Advisors’s Mersana Therapeutics MRSN Stock Holding History

Nordwand Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$2.83K – 129
2024
Q3 		$2.83K Hold
60
– – ﹤0.01% 112
2024
Q2 		$3.02K Buy
+60
New +$4.34K ﹤0.01% 136

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Nordwand Advisors's MRSN Position: Q4 2024 in Review

Nordwand Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 60 shares — an estimated $2.83K sold.

Nordwand Advisors first reported a position in MRSN in Q2 2024 and held it in 2 quarters. The position peaked at $3.02K in Q2 2024. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Nordwand Advisors reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 60 Mersana Therapeutics shares in Q4 2024, an estimated $2.83K.
  • Nordwand Advisors first reported a position in Mersana Therapeutics in Q2 2024 and held it in 2 quarters.
  • Nordwand Advisors's Mersana Therapeutics position peaked at $3.02K in Q2 2024.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.